Exploring new ways to block protein interactions in cancer treatment

Covalent PD1 Antagonists: Discovery of Protein-Protein Interaction (PPI) Inhibitors in Cancer Immunotherapy

NIH-funded research Florida Atlantic University · NIH-10994616

This study is exploring new ways to block certain protein interactions that help cancer grow, using special tools and techniques, with the hope of creating better treatments that could help patients respond more effectively to cancer therapy.

Quick facts

Grant typeR03 grant
Study typeNIH-funded research
Funding institutionFlorida Atlantic University NIH-funded
Lab location1 site (Boca Raton, United States)
Project IDNIH-10994616 on NIH RePORTER

What this research studies

This research investigates innovative methods to inhibit protein-protein interactions (PPIs) that are crucial in cancer biology. By utilizing advanced proteomic tools and gene-editing techniques, the project aims to develop novel PPI inhibitors using β-hairpin peptides that mimic antibody structures. This approach seeks to enhance the specificity and effectiveness of cancer immunotherapy by targeting specific interactions that contribute to tumor growth and immune evasion. Patients may benefit from new therapeutic options that could improve their response to cancer treatment.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with cancer who may benefit from new immunotherapy treatments.

Not a fit: Patients with non-cancerous conditions or those who do not respond to immunotherapy may not receive benefits from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that enhance the body's ability to fight tumors.

How similar studies have performed: Other research has shown promise in targeting protein-protein interactions for cancer treatment, indicating that this approach could be a viable strategy.

Where this research is happening

Boca Raton, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions anti-cancer immunotherapy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.